Kuros Biosciences AG (SWX:KURN)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
32.30
+0.14 (0.44%)
Oct 21, 2025, 5:31 PM CET
0.44%
Market Cap1.25B
Revenue (ttm)103.35M
Net Income (ttm)-6.07M
Shares Out38.94M
EPS (ttm)-0.13
PE Ration/a
Forward PE109.02
Dividendn/a
Ex-Dividend Daten/a
Volume217,443
Average Volume299,752
Open31.68
Previous Close32.16
Day's Range31.18 - 32.34
52-Week Range14.00 - 34.20
Beta0.60
RSI67.89
Earnings DateMar 10, 2026

About Kuros Biosciences AG

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bon... [Read more]

Sector Healthcare
Founded 2016
Employees 122
Stock Exchange SIX Swiss Exchange
Ticker Symbol KURN
Full Company Profile

Financial Performance

In 2024, Kuros Biosciences AG's revenue was 75.56 million, an increase of 125.11% compared to the previous year's 33.56 million. Losses were -4.29 million, -68.75% less than in 2023.

Financial Statements

News

Kuros 9-month Revenue Up 77%; Raises 2025 Sales Guidance

(RTTNews) - Kuros Biosciences (KURN.SW) reported that, for the first nine months of 2025, total group revenue was $101.1 million, up by 77% compared with the same period in 2024. Revenue from Direct M...

5 days ago - Nasdaq